Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 Clinical Trials Drug Approval Standards

Lilly Seeks EUA For COVID-19 Antibody, Unveils Positive Combo Data

  • Analysis

Executive Summary

Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.

You may also be interested in...



Coronavirus Update: Indian Vaccine Makers Highlight US Component Constraints

A roundup of the latest global developments around COVID-19, including progress in Asia for Moderna's vaccine, promising results for a Lilly antibody combo, and new vaccine support moves by CEPI.   

Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations

The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.

Coronavirus Update: Lilly To Seek EUA For Olumiant

Hot on the heels of positive news from its monoclonal antibody treatment, Lilly aims to seek emergency authorization for anti-inflammatory treatment Olumiant.

Table

View full table

Related Content

Scrip
Scrip
Scrip
Scrip
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 Clinical Trials Drug Approval Standards
UsernamePublicRestriction

Register

SC143095

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By